Skip to content
Symbiotec Pharmalab logo

Symbiotec Pharmalab IPO

Check allotment status
Issue price
₹988
Listing price
₹988
0.00%
Current price
₹1,611.3
+63.09%
Subscribed
71.26x
Issue size
₹1,757 Cr
Listed on
1 Sep 2026

IPO timeline

  1. Opens
    24 AugMon
  2. Closes
    27 AugThu
  3. Allotment
    28 AugFri
  4. Refunds
    31 AugMon
  5. Demat credit
    31 AugMon
  6. Listing
    1 SepTue

Issue details

Price band
₹938 – ₹988 per share
Issue size
₹1,757 Cr
Fresh issue
Not available
Offer for sale
Not available
Issue type
Fresh capital cum OFS
Face value
₹2 per share
Lot size
15 shares
Minimum investment
₹14,820
Listing on
BSE, NSE
Exchange code
SYMBIOTEC · 7907

This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.

Lot size and investment

ApplicationLotsSharesAmount
Retail (Min)115₹14,820
Retail (Max)13195₹1,92,660
S-HNI (Min)14210₹2,07,480
B-HNI (Min)681,020₹10,07,760

Reservation

QIB
Not more than 50% of the Net Offer
Retail
Not less than 35.00% of the Net Offer
NII
Not less than 15% of the Net Offer

Allotment status

Registrar: MUFG Intime India Private Limited

The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).

Check allotment on MUFG Intime India
  1. 1Open the registrar's allotment page and select this IPO from the list.
  2. 2Enter your PAN, application number or DP / Client ID.
  3. 3Submit to see the number of shares allotted, if any.
Basis of allotment
28 Aug 2026
Refunds initiated
31 Aug 2026
Shares credited to demat
31 Aug 2026
Listing
1 Sep 2026
Basis of allotment document

Grey market premium (GMP)

Updated 01 Sep 2026, 08:24 AM IST
Current GMP
₹185
+18.72%
Estimated listing price
₹1,173
Issue price ₹988
Highest
₹410
22 Aug
Lowest
₹185
31 Aug

GMP by day (₹ per share)

Day-wise GMP table
DateGMPPremiumEst. listing
1 Sep 2026₹185+18.72%₹1,173
31 Aug 2026₹185+18.72%₹1,173
30 Aug 2026₹240+24.29%₹1,228
29 Aug 2026₹240+24.29%₹1,228
28 Aug 2026₹265+26.82%₹1,253
27 Aug 2026₹270+27.33%₹1,258
26 Aug 2026₹295+29.86%₹1,283
25 Aug 2026₹352+35.63%₹1,340
24 Aug 2026₹335+33.91%₹1,323
23 Aug 2026₹409+41.40%₹1,397
22 Aug 2026₹410+41.50%₹1,398
21 Aug 2026₹345+34.92%₹1,333
20 Aug 2026₹300+30.36%₹1,288
19 Aug 2026₹220+22.27%₹1,208

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

Subscription status

Updated 01 Sep 2026, 06:31 PM IST
Overall subscription
71.26x
Fully subscribed · 51,73,193 applications
  • QIB172.03x
  • NII (HNI)73.63x
  • Retail12.96x
  • Employee15.41x
CategoryShares offeredShares bid forSubscribed
Qualified Institutional Buyers (QIB)37,39,87264,33,59,195172.03x
Non-Institutional Investors (NII)28,04,90420,65,35,12073.63x
bNII — bids above ₹10 Lakh18,69,93615,50,46,49582.92x
sNII — bids ₹2 Lakh to ₹10 Lakh9,34,9685,14,88,62555.07x
Retail Individual Investors (RII)65,44,7768,48,10,33012.96x
Employee35,3775,45,05515.41x
Total1,31,24,92993,52,49,70071.26x

Financials

Amounts in Rs. Crore
P/E Ratio
56.81
EPS (₹)
17.39
RoE
11.19%
RoCE
11.56%
RoNW
9.48%
PAT Margin
12.60%
EBITDA Margin
26.59%
NAV (₹)
184.69

Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.

Period ended31 Mar 202631 Mar 202531 Mar 2024
Assets1,780.791,579.651,294.79
Total Income872.26755.98723.33
Profit After Tax109.9096.79100.06
EBITDA231.97206.11177.04
NET Worth1,158.64821.15720.68
Reserves and Surplus1,145.95810.03709.54
Total Borrowing387.91540.92247.21
CompanyIssue sizeP/ERoNWPAT marginSubscribedListing gain
Symbiotec Pharmalab
This IPO
₹1,757 Cr56.819.48%12.60%71.26x0.00%
Indegene
Mainboard · listed 13 May 2024
₹1,841.76 Cr33.5318.23%12.62%70.3x+44.91%
Akums Drugs & Pharmaceuticals
Mainboard · listed 6 Aug 2024
₹1,856.74 Cr13580-0.57%0.02%63.44x+6.77%
Entero Healthcare Solutions
Mainboard · listed 16 Feb 2024
₹1,600 Cr129.75-1.86%4.69%1.56x-2.33%
Sagility India
Mainboard · listed 12 Nov 2024
₹2,106.4 Cr61.520.29%11.83%3.2x+3.53%
Paras Healthcare
Mainboard · listed 28 Oct 2026
₹1,450 Cr37.7211.83%10.38%2.23x+3.90%
Rubicon Research
Mainboard · listed 16 Oct 2025
₹1,378 Cr46.1329.02%10.37%109.32x+27.84%

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

IPO objectives

₹112.5 Cr total

How Symbiotec Pharmalab plans to use the money raised, as stated in the offer document.

  1. Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company₹112.5 Cr
  2. General corporate purposes

About Symbiotec Pharmalab

Symbiotec Pharmalab Ltd was set up in 2002. It is a pharmaceutical and biotechnology company that develops and makes active pharmaceutical ingredients, known as APIs, along with nutritional ingredients and specialty products. APIs are the actual medicine content that goes into a tablet or injection, which other pharma companies then turn into finished medicines. The company started in 1995 as a small lab scale maker of steroidal hormone APIs and has grown into a large backward integrated manufacturer with more than 30 years of experience in the field. It is a global leader in corticosteroid and steroidal hormone APIs. Its plants are approved by the United States Food and Drug Administration, by European Union Good Manufacturing Practices and by the Ministry of Food and Drug Safety of Korea, among other regulators. As on 30 June 2025 it ran two industrial scale API plants with a chemical synthesis capacity of 584.67 metric tonnes and a fermentation capacity of 300 kilolitres. It sells both in India and abroad, in regulated as well as emerging markets.

Strengths

  • The company is a global leader in corticosteroid and steroidal hormone APIs, which is a specialised area with few makers worldwide.
  • Its plants carry approvals from the US FDA, EU-GMP and the Korean drug regulator, which are hard to get and act as an entry barrier.
  • Sales have grown every year, from Rs 723.33 crore in FY2024 to Rs 755.98 crore in FY2025 and Rs 872.26 crore in FY2026.
  • EBITDA has improved steadily, from Rs 177.04 crore in FY2024 to Rs 206.11 crore in FY2025 and Rs 231.97 crore in FY2026.
  • Borrowing was reduced sharply in the last year, from Rs 540.92 crore to Rs 387.91 crore, while net worth rose from Rs 821.15 crore to Rs 1,158.64 crore.
  • The company is backward integrated and runs at industrial scale, with chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
  • It has more than 30 years of experience in this line, having started as a lab scale steroid API maker in 1995.
  • It sells into both regulated markets such as the USA and Europe and into emerging markets, so demand is not tied to one region.

Risks

  • This is by far the most expensive issue in the current batch on earnings. At the upper band of Rs 988 the P/E is about 56.81 times on an EPS of Rs 17.39.
  • Return ratios are low for that valuation. RoCE was 11.80% and RoNW was 11.79%.
  • Profit has been almost flat for three years, at Rs 100.06 crore in FY2024, Rs 96.79 crore in FY2025 and Rs 109.90 crore in FY2026, even though assets grew from Rs 1,294.79 crore to Rs 1,780.79 crore over the same period.
  • Very little of the issue money reaches the company. The stated objects account for only Rs 112.50 crore of borrowing repayment plus general corporate purposes, against a total issue of Rs 1,757 crore, which indicates that most of the issue is an offer for sale by existing shareholders.
  • The pre issue and post issue promoter holding is not stated in the available data, so the extent of promoter dilution is not clear.
  • API making is a regulated business. A negative inspection by the US FDA or the EU authorities at either plant can stop supply to those markets.
  • The company is concentrated in steroid and corticosteroid APIs. A price fall or new capacity in that narrow segment would hit it directly.
  • Borrowing is still sizeable at Rs 387.91 crore, and it had risen to Rs 540.92 crore in FY2025 before coming down, so the debt level has moved around a lot.

Promoters and shareholding

Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP

Anchor investors

34 investors · ₹526.19 Cr raised
InvestorShares allottedAmount% of anchor book
ICICI PRUDENTIAL SMALLCAP FUND6,07,290₹60 Cr11.4%
HDFC PHARMA & HEALTHCARE FUND4,04,865₹40 Cr7.6%
HDFC MNC FUND50,610₹5 Cr0.95%
ASHOKA WHITEOAK ICAV-ASHOKA WHITEOAK EMERGING MARKETS EQUITY FUND4,55,475₹45 Cr8.55%
MOTILAL OSWAL SMALL CAP FUND4,55,475₹45 Cr8.55%
MIRAE ASSET HEALTHCARE FUND3,54,270₹35 Cr6.65%
MIRAE ASSET MULTI ASSET ALLOCATION FUND1,01,205₹10 Cr1.9%
PRAZIM TRADING & INVESTMENT CO.PVT.LTD.2,53,050₹25 Cr4.75%
TATA INDIA PHARMA & HEALTHCARE FUND1,01,220₹10 Cr1.9%
TATA FLEXI CAP FUND1,51,830₹15 Cr2.85%
EDELWEISS LARGE CAP FUND2,02,425₹20 Cr3.8%
EDELWEISS RECENTLY LISTED IPO FUND50,625₹5 Cr0.95%
MANULIFE GLOBAL FUND-INDIA EQUITY FUND2,53,050₹25 Cr4.75%
MAHINDRA MANULIFE SMALL CAP FUND2,53,050₹25 Cr4.75%
TATA AIA LIFE INSURANCE CO.LTD.-WHOLE LIFE AGGRESSIVE GROWTH FUND-ULIF 010 04/01/07 WLA 1101,61,955₹16 Cr3.04%
BAJAJ LIFE INSURANCE LTD.1,61,955₹16 Cr3.04%
BARODA BNP PARIBAS HEALTH & WELLNESS FUND60,720₹6 Cr1.14%
BARODA BNP PARIBAS FOCUSED FUND1,01,235₹10 Cr1.9%
BHARTI AXA LIFE INSURANCE CO.LTD.1,01,220₹10 Cr1.9%
TIMF HOLDINGS1,01,220₹10 Cr1.9%
VALUEQUEST FOUNDERS CONVICTION LVF1,01,220₹10 Cr1.9%
TRUST MF MULTI CAP FUND50,610₹5 Cr0.95%
TRUST MF LARGE & MID CAP FUND50,610₹5 Cr0.95%
GROWW MULTICAP FUND70,860₹7 Cr1.33%
GROWW SMALL CAP FUND30,360₹3 Cr0.57%
FLUMEN INVESTMENT TRUST-1729 GROWTH FUND I50,610₹5 Cr0.95%
RMS GROWTH FUND SCHEME I50,610₹5 Cr0.95%
SUSQUEHANNA PACIFIC PTY.LTD.1,01,220₹10 Cr1.9%
SINGULARITY EQUITY FUND I1,01,220₹10 Cr1.9%
ITI MULTI CAP FUND50,610₹5 Cr0.95%
ITI FLEXI CAP FUND50,610₹5 Cr0.95%
ICICI LOMBARD GENERAL INSURANCE CO.LTD.88,331₹8.73 Cr1.66%
BNP PARIBAS FINANCIAL MARKETS-ODI88,330₹8.73 Cr1.66%
CITIGROUP GLOBAL MARKETS MAURITIUS PVT.LTD.57,963₹5.73 Cr1.09%

Registrar, lead managers and documents

Registrar

MUFG Intime India Private Limited

022-49186000

symbiotecpharmalab.ipo@in.mpms.mufg.com

Company contact

385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331

+91 731 667 6405

secretarial@symbiotec.com

Symbiotec Pharmalab IPO: common questions

1.When does the Symbiotec Pharmalab IPO open and close?

The Symbiotec Pharmalab IPO opens on 24 Aug 2026 and closes on 27 Aug 2026.

2.What is the price band of the Symbiotec Pharmalab IPO?

The price band is ₹938 – ₹988 per share, with a lot size of 15 shares and a minimum investment of ₹14,820.

3.What is the size of the Symbiotec Pharmalab IPO?

The issue size is ₹1,757 Cr (Fresh capital cum OFS).

4.What is the GMP of the Symbiotec Pharmalab IPO?

The last reported grey market premium is ₹185 per share as of 01 Sep 2026, 08:24 AM IST. GMP is unofficial and changes frequently.

5.When is the Symbiotec Pharmalab IPO allotment?

The basis of allotment is expected on 28 Aug 2026. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.

6.When will the Symbiotec Pharmalab IPO list?

The shares listed on 1 Sep 2026 on BSE, NSE.

7.Who is the lead manager of the Symbiotec Pharmalab IPO?

The book running lead managers are JM Financial Ltd., Motilal Oswal Investment Advisors, Avendus Capital, and the registrar is MUFG Intime India Private Limited.

8.What will the money raised in the Symbiotec Pharmalab IPO be used for?

As stated in the offer document, the proceeds are for: Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company; General corporate purposes.

9.How can my company launch an IPO like Symbiotec Pharmalab?

Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.

For business owners

Your company could be the next listing

Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.

  • Eligibility check against NSE Emerge, BSE SME and Main Board norms
  • Indicative valuation and issue size for your business
  • A clear timeline from readiness to listing day

Check if your business can list

Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.

Prefer to talk? Call +91 92130 20393